News & Events
October 7, 2021
Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the round follows promising 2020 and 2021 preclinical data demonstrating the effectiveness of Sapreme’s endosomal escape compound, SPT001. Read the full release here.
Events:
Upcoming events:
Please check back for future event updates
Past events:
8 – 9 March, 2023 | Boston, MA – Targeted Intracellular Delivery Summit
We will be delivering a talk at the first Targeted Intracellular Delivery Summit, in which Sapreme’s highly differentiated tissue specific targeted, intracellular delivery technology will be highlighted. The Targeted Intracellular Delivery Summit is a new and unique industry touchpoint for optimising the therapeutic index of complex-payload pipelines through novel targeted delivery systems & overcoming critical endosomal biological barriers. We look forward to sharing our insights and meeting up with the many other trailblazers, current and potential future partners in Boston in March.
9 – 11 January, 2023 | San Francisco- JP Morgan Week | Bio 2023
Guy Hermans (CEO) will be returning to San Francisco to represent Sapreme during JPM week. He is looking forward to discuss our recent achievements and is welcoming opportunities to meet current and future partners to explain our delivery technology and explore how we might collaborate together. Meeting requests are best send through the Bio Partnering system, or send a message to info@sapreme-technologies.com.
13 – 15 June, 2022 | Boston, MA – 2nd Annual Oligonucleotides for CNS Summit
Miriam Bujny (CDO) will be making an appearance at the 2nd Annual Oligonucleotides for CNS summit in Boston June 13-15. She will be delivering a talk on Efficient on-target delivery of oligonucleotides, showcasing in vitro and in vivo performance of Sapreme’s endosomal escape enhancers for various tissues and targets.
13 – 16 June, 2022 | San Diego, CA – BIO International Convention 2022
In the week of 13 – 16 June, Sapreme will be represented at BIO 2022 in San Diego by Guy Hermans (CEO) and Henrik Luessen (Chief Business Officer). They are primed and ready to meet our current and future partners, explain our targeted, intracellular delivery technology and talk about how we might collaborate together towards truly innovative therapeutics. Do reach out should you find yourself here, Guy Hermans and Henrik Luessen would be delighted to catch up.
13 – 16 June, 2022 | San Diego, CA – BIO International Convention 2022
In the week of 13 – 16 June, Sapreme will be represented at BIO 2022 in San Diego by Guy Hermans (CEO) and Henrik Luessen (Chief Business Officer). They are primed and ready to meet our current and future partners, explain our targeted, intracellular delivery technology and talk about how we might collaborate together towards truly innovative therapeutics. Do reach out should you find yourself here, Guy Hermans and Henrik Luessen would be delighted to catch up.
20 & 21 April, 2022 | Boston, MA – 3rd Annual RNAi-based Therapeutics Summit
Guy Hermans (CEO) will be attending, and speaking at the 3rd Annual RNAi-Based Therapeutics Summit. His presentation on “Efficient on-target delivery of oligonucleotides to the liver and beyond: in vitro performance of Sapreme’s endosomal escape enhancers” at the start of the first day is one not to miss!
25 – 27 April, 2022 | Boston, MA – Novel Format Conjugates Summit
Ruben Postel, founder and CSO, will be speaking in person on Tuesday 26th April at the Novel Format Conjugates Summit in Boston, MA. In his talk, he will discuss improved receptor-targeted cytoplasmic delivery of macromolecule payloads using Sapreme’s endosomal escape enhancers.
About Sapreme:
Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.
Contacts: Guy Hermans, CEO +31 30 760 09 76 hermans@sapreme-technologies.com
For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher +49 89 238 877 30 sapreme@trophic.eu